A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Clinical trial NCT07335562 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07335562
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-29
- Primary completion
- 2028-11-14
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.